Mikhail Blagosklonny believes that cancer is curable and aging is controllable. He is as prolific a research scientist as one could ever meet. He has written and published 300 research articles, book chapters, and reviews. He also functions as an associate editor for PLOS ONE, the American Journal of Pathology, and International Journal of Cancer. Blagosklonny is without question the preeminent Oncology researcher in the world.
In addition to cancer, Dr. Blagosklonny other research interests are Biogerontology, anti-aging drugs, and targeted cancer therapies that protect healthy cells. He is a Professor of Oncology at the Roswell Park Cancer Institute, and a scientist interested in controlling the aging process. Professor Blagosklonny has worked in a variety of positions and locations with each one giving him the opportunity to add to his skill and experience. View Mikhail’s profile in LinkedIn
He earned his Medical Degree in Internal Medicine from the First Pavlov State Medical University of St. Petersburg, where he continued to attend eventually earning a Ph.D. in Experimental Medicine and Cardiology. In, 2002 He became the associate professor of medicine at New York Medical College where he served until becoming the senior scientist at Ordway Research Institute. And in 2009 began working at Roswell Park.
One of the most promising discoveries Dr. Mikhail Blagosklonny has uncovered involves a drug called Rapamycin. In 2006, researchers concluded that Rapamycin was already approved by the USDA and was available for immediate use. All diseases related to aging like osteoporosis or Alzheimer’s is treatable with the drug. Rapamycin also shows effectiveness in treating cancer, cardiovascular disease, autoimmune and metabolic disorders.
The most fantastic use of what some are calling the fountain-of-youth drug affects anti-aging. Simply put, Rapamycin rejuvenates the immunity. The drug makes one’s immune system function as though it was young again. Traditionally aging was thought to be an unchallengeable natural order where the accumulation of molecular damage causes functional decline.
When Professor Blagosklonny came up with a new theory called hyperfunction theory, many of his peers ridiculed his hypothesis. Those same scientists and researchers have since changed their opinions. Science now understands that Rapamycin, when used correctly, treats diseases and aging in humans but can also extend human lifespans.